Autopsy report · NCT07585734

Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia

“drug-associated adverse reactions”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Sponsor type

University, hospital or other

Conditions

T-ALL

Interventions

Pediatric-Inspired Chemotherapy Regimen

Participants

0

Trials that died the same way

• Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)
  “investigation of adverse events in a related clinical study” (73% match in meaning)
• Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
  “Adverse Events” (68% match in meaning)
• Safety and Preliminary Efficacy Study of V404 PDS in Uveitis
  “Study terminated due to unacceptable frequency of drug related adverse events” (66% match in meaning)
• Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes
  “Unexpected non-serious adverse events” (63% match in meaning)
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
  “Other - Adverse Events” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.